New prostate cancer pill enters human testing
NCT ID NCT04853498
Summary
This was an early-stage study to find a safe dose and understand how the body processes a new oral drug called TQB3720. It involved 192 men whose prostate cancer had spread and stopped responding to standard hormone treatments. The main goals were to check for side effects and measure how much of the drug gets into the bloodstream.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200035, China
Conditions
Explore the condition pages connected to this study.